New approaches for improving engraftment after cord blood transplantation.

Vanderson Rocha, Hal Broxmeyer

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Use of unrelated umbilical cord blood cells (UCB) as an alternative source of hematopoietic cell transplantation (HCT) has been widely used mainly for patients lacking an HLA-matched donor. There are many advantages for using CB cells over bone marrow or mobilized peripheral blood (MBP) from volunteer donors, such as rapid availability, absence of risk for the donor, or decreased incidence of acute graft-versus-host disease (aGVHD). However, a significant clinical problem is delayed engraftment, which is directly correlated with the number of hematopoietic stem cells (HSCs) in a CB unit. The understanding of methods to improve collection, expansion, and homing of CB cells, the identification of prognostic factors associated with engraftment that can be easily modified (eg, strategies for donor choice), and development of new approaches including use of multiple donors, cotransplantation with accessory cells are of crucial importance to circumvent the problem of delayed engraftment after UCB transplantation. Those approaches may greatly increase the quality and availability of CB for transplantation.

Original languageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number1 Suppl
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Fetal Blood
Transplantation
Tissue Donors
Cell Transplantation
Blood Cells
Graft vs Host Disease
Hematopoietic Stem Cells
Blood Donors
Bone Marrow Cells
Volunteers
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

New approaches for improving engraftment after cord blood transplantation. / Rocha, Vanderson; Broxmeyer, Hal.

In: Biology of Blood and Marrow Transplantation, Vol. 16, No. 1 Suppl, 01.2010.

Research output: Contribution to journalArticle

@article{cd2900b08a3f461b93ea2fca08adc9b2,
title = "New approaches for improving engraftment after cord blood transplantation.",
abstract = "Use of unrelated umbilical cord blood cells (UCB) as an alternative source of hematopoietic cell transplantation (HCT) has been widely used mainly for patients lacking an HLA-matched donor. There are many advantages for using CB cells over bone marrow or mobilized peripheral blood (MBP) from volunteer donors, such as rapid availability, absence of risk for the donor, or decreased incidence of acute graft-versus-host disease (aGVHD). However, a significant clinical problem is delayed engraftment, which is directly correlated with the number of hematopoietic stem cells (HSCs) in a CB unit. The understanding of methods to improve collection, expansion, and homing of CB cells, the identification of prognostic factors associated with engraftment that can be easily modified (eg, strategies for donor choice), and development of new approaches including use of multiple donors, cotransplantation with accessory cells are of crucial importance to circumvent the problem of delayed engraftment after UCB transplantation. Those approaches may greatly increase the quality and availability of CB for transplantation.",
author = "Vanderson Rocha and Hal Broxmeyer",
year = "2010",
month = "1",
language = "English (US)",
volume = "16",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1 Suppl",

}

TY - JOUR

T1 - New approaches for improving engraftment after cord blood transplantation.

AU - Rocha, Vanderson

AU - Broxmeyer, Hal

PY - 2010/1

Y1 - 2010/1

N2 - Use of unrelated umbilical cord blood cells (UCB) as an alternative source of hematopoietic cell transplantation (HCT) has been widely used mainly for patients lacking an HLA-matched donor. There are many advantages for using CB cells over bone marrow or mobilized peripheral blood (MBP) from volunteer donors, such as rapid availability, absence of risk for the donor, or decreased incidence of acute graft-versus-host disease (aGVHD). However, a significant clinical problem is delayed engraftment, which is directly correlated with the number of hematopoietic stem cells (HSCs) in a CB unit. The understanding of methods to improve collection, expansion, and homing of CB cells, the identification of prognostic factors associated with engraftment that can be easily modified (eg, strategies for donor choice), and development of new approaches including use of multiple donors, cotransplantation with accessory cells are of crucial importance to circumvent the problem of delayed engraftment after UCB transplantation. Those approaches may greatly increase the quality and availability of CB for transplantation.

AB - Use of unrelated umbilical cord blood cells (UCB) as an alternative source of hematopoietic cell transplantation (HCT) has been widely used mainly for patients lacking an HLA-matched donor. There are many advantages for using CB cells over bone marrow or mobilized peripheral blood (MBP) from volunteer donors, such as rapid availability, absence of risk for the donor, or decreased incidence of acute graft-versus-host disease (aGVHD). However, a significant clinical problem is delayed engraftment, which is directly correlated with the number of hematopoietic stem cells (HSCs) in a CB unit. The understanding of methods to improve collection, expansion, and homing of CB cells, the identification of prognostic factors associated with engraftment that can be easily modified (eg, strategies for donor choice), and development of new approaches including use of multiple donors, cotransplantation with accessory cells are of crucial importance to circumvent the problem of delayed engraftment after UCB transplantation. Those approaches may greatly increase the quality and availability of CB for transplantation.

UR - http://www.scopus.com/inward/record.url?scp=77953044213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953044213&partnerID=8YFLogxK

M3 - Article

C2 - 19896543

AN - SCOPUS:77953044213

VL - 16

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1 Suppl

ER -